Cite
MLA Citation
Christophe Le Tourneau et al.. “793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A474. http://access.bl.uk/ark:/81055/vdc_100144715758.0x000005